KRAS is altered in 14.7% of malignant solid tumor patients with KRAS Mutation present in 13.82% of all malignant solid tumor patients [4].

KRAS Mutation is an inclusion criterion in 46 clinical trials for malignant solid tumor, of which 30 are open and 16 are closed. Of the trials that contain KRAS Mutation and malignant solid tumor as inclusion criteria, 27 are phase 1 (15 open), 9 are phase 1/phase 2 (7 open), and 10 are phase 2 (8 open) [5].

KRAS is altered in 26.66% of non-small cell lung carcinoma patients with KRAS Mutation present in 26.1% of all non-small cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 38 clinical trials for non-small cell lung carcinoma, of which 30 are open and 8 are closed. Of the trials that contain KRAS Mutation and non-small cell lung carcinoma as inclusion criteria, 21 are phase 1 (16 open), 4 are phase 1/phase 2 (3 open), 12 are phase 2 (10 open), and 1 is phase 3 (1 open) [5].

KRAS is altered in 40.06% of colorectal carcinoma patients with KRAS Mutation present in 39.67% of all colorectal carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 23 clinical trials for colorectal carcinoma, of which 15 are open and 8 are closed. Of the trials that contain KRAS Mutation and colorectal carcinoma as inclusion criteria, 15 are phase 1 (10 open), 6 are phase 1/phase 2 (4 open), and 2 are phase 2 (1 open) [5].

KRAS is altered in 2.67% of melanoma patients with KRAS Mutation present in 2.24% of all melanoma patients [4].

KRAS Mutation is an inclusion criterion in 10 clinical trials for melanoma, of which 7 are open and 3 are closed. Of the trials that contain KRAS Mutation and melanoma as inclusion criteria, 8 are phase 1 (5 open) and 2 are phase 1/phase 2 (2 open) [5].

KRAS is altered in 3.87% of acute myeloid leukemia patients with KRAS Mutation present in 3.87% of all acute myeloid leukemia patients [4].

KRAS Mutation is an inclusion criterion in 9 clinical trials for acute myeloid leukemia, of which 7 are open and 2 are closed. Of the trials that contain KRAS Mutation and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 3 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

KRAS is altered in 70.4% of pancreatic carcinoma patients with KRAS Mutation present in 70.31% of all pancreatic carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 7 clinical trials for pancreatic carcinoma, of which 5 are open and 2 are closed. Of the trials that contain KRAS Mutation and pancreatic carcinoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 1.75% of breast carcinoma patients with KRAS Mutation present in 0.7% of all breast carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 7 clinical trials for breast carcinoma, of which 4 are open and 3 are closed. Of the trials that contain KRAS Mutation and breast carcinoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [5].

KRAS is altered in 9.67% of ovarian carcinoma patients with KRAS Mutation present in 7.81% of all ovarian carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for ovarian carcinoma, of which 4 are open and 2 are closed. Of the trials that contain KRAS Mutation and ovarian carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 1.67% of non-hodgkin lymphoma patients with KRAS Mutation present in 1.67% of all non-hodgkin lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 4 are open and 2 are closed. Of the trials that contain KRAS Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [5].

KRAS is altered in 1.34% of myelodysplastic syndromes patients with KRAS Mutation present in 1.34% of all myelodysplastic syndromes patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for myelodysplastic syndromes, of which 5 are open and 1 is closed. Of the trials that contain KRAS Mutation and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

KRAS is altered in 11.11% of chronic myelomonocytic leukemia patients with KRAS Mutation present in 11.11% of all chronic myelomonocytic leukemia patients [4].

KRAS Mutation is an inclusion criterion in 5 clinical trials for chronic myelomonocytic leukemia, of which 4 are open and 1 is closed. Of the trials that contain KRAS Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

KRAS is altered in 70.42% of pancreatic adenocarcinoma patients with KRAS Mutation present in 70.32% of all pancreatic adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and pancreatic adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 40.23% of colorectal adenocarcinoma patients with KRAS Mutation present in 39.83% of all colorectal adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for colorectal adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain KRAS Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

KRAS is altered in 29.71% of lung adenocarcinoma patients with KRAS Mutation present in 29.16% of all lung adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for lung adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 9.91% of acute lymphoblastic leukemia patients with KRAS Mutation present in 9.91% of all acute lymphoblastic leukemia patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 1 is closed. Of the trials that contain KRAS Mutation and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 6.23% of bladder carcinoma patients with KRAS Mutation present in 5.54% of all bladder carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for bladder carcinoma, of which 3 are open and 1 is closed. Of the trials that contain KRAS Mutation and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].

KRAS is altered in 11.56% of esophageal carcinoma patients with KRAS Mutation present in 3.2% of all esophageal carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for esophageal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain KRAS Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [5].

KRAS Mutation is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 39.02% of colon carcinoma patients with KRAS Mutation present in 38.49% of all colon carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [5].

KRAS is altered in 16.89% of endometrial carcinoma patients with KRAS Mutation present in 16.54% of all endometrial carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 0.99% of renal cell carcinoma patients with KRAS Mutation present in 0.99% of all renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and renal cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 0.93% of prostate carcinoma patients with KRAS Mutation present in 0.74% of all prostate carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

KRAS is altered in 76.19% of pancreatic ductal adenocarcinoma patients with KRAS Mutation present in 76.19% of all pancreatic ductal adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 14.83% of cholangiocarcinoma patients with KRAS Mutation present in 14.32% of all cholangiocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 14.59% of cancer patients with KRAS Mutation present in 13.75% of all cancer patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and cancer as inclusion criteria, 2 are phase 1 (1 open) [5].

KRAS is altered in 10.13% of gastric carcinoma patients with KRAS Mutation present in 6.9% of all gastric carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (0 open) [5].

KRAS is altered in 5.64% of urothelial carcinoma patients with KRAS Mutation present in 5.03% of all urothelial carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 4.74% of squamous cell lung carcinoma patients with KRAS Mutation present in 4.02% of all squamous cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 3.76% of poorly differentiated thyroid gland carcinoma patients with KRAS Mutation present in 3.76% of all poorly differentiated thyroid gland carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

KRAS is altered in 2.2% of cutaneous melanoma patients with KRAS Mutation present in 1.88% of all cutaneous melanoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for cutaneous melanoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open) [5].

KRAS is altered in 1.83% of glioma patients with KRAS Mutation present in 1.21% of all glioma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

KRAS is altered in 1.44% of glioblastoma patients with KRAS Mutation present in 0.89% of all glioblastoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

KRAS is altered in 44.19% of malignant small intestinal neoplasm patients with KRAS Mutation present in 44.19% of all malignant small intestinal neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 40.19% of malignant intestinal neoplasm patients with KRAS Mutation present in 39.81% of all malignant intestinal neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 27.46% of low grade ovarian serous adenocarcinoma patients with KRAS Mutation present in 27.46% of all low grade ovarian serous adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 25.73% of lung carcinoma patients with KRAS Mutation present in 25.18% of all lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 21.47% of germ cell tumor patients with KRAS Mutation present in 8.97% of all germ cell tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

KRAS is altered in 9.75% of malignant ovarian epithelial tumor patients with KRAS Mutation present in 7.67% of all malignant ovarian epithelial tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 23.31% of malignant testicular neoplasm patients with KRAS Mutation present in 7.43% of all malignant testicular neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant testicular neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant testicular neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 10.13% of malignant gastric neoplasm patients with KRAS Mutation present in 6.9% of all malignant gastric neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 11.12% of malignant esophagogastric neoplasm patients with KRAS Mutation present in 4.84% of all malignant esophagogastric neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 3.85% of papillary renal cell carcinoma patients with KRAS Mutation present in 3.85% of all papillary renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 3.63% of lymphoma patients with KRAS Mutation present in 3.63% of all lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 3.25% of myeloid neoplasm patients with KRAS Mutation present in 3.25% of all myeloid neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 3.52% of small cell lung carcinoma patients with KRAS Mutation present in 3.02% of all small cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 2.65% of thyroid gland carcinoma patients with KRAS Mutation present in 2.65% of all thyroid gland carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 2.7% of low grade glioma patients with KRAS Mutation present in 2.55% of all low grade glioma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 3.15% of squamous cell carcinoma patients with KRAS Mutation present in 2.44% of all squamous cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 4.34% of high grade ovarian serous adenocarcinoma patients with KRAS Mutation present in 1.84% of all high grade ovarian serous adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS is altered in 1.82% of thyroid gland papillary carcinoma patients with KRAS Mutation present in 1.82% of all thyroid gland papillary carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 1.74% of sarcoma patients with KRAS Mutation present in 1.36% of all sarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is altered in 1.53% of soft tissue sarcoma patients with KRAS Mutation present in 1.22% of all soft tissue sarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS is altered in 1.01% of kidney carcinoma patients with KRAS Mutation present in 1.01% of all kidney carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and kidney carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 1.74% of breast adenocarcinoma patients with KRAS Mutation present in 0.67% of all breast adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is altered in 2.64% of anaplastic astrocytoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].